

Ref No. NLL/CS/2019- 246

Date: 11.02.2019

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla
Complex,
Bandra (East), MUMBAI – 400 051.

2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Financial Results.

**Ref: Compliance Pursuant to Regulation 33 of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Sir's,

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Un-audited Standalone Financial results for the quarter & nine months period ended on December 31, 2018 which are enclosed herewith along with the Limited Review Report of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Nectar Lifesciences Limited


(Ankita Jain)
Company Secretary

Encl: a.a.

To Whomsoever It May Concern

We have reviewed the accompanying statement of unaudited financial results of **Nectar Lifesciences Limited** for the quarter and half year ended **December 31, 2018** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulation 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim financial information performed by Independent Auditors of the Entity* issued by the Institute of Chartered Accountant of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Ashwani K. Gupta & Associates
Chartered Accountants
Firm Regn. No. 003803N


(ASHWANI KUMAR GUPTA)
PARTNER
Membership No.: 082808

Place: Chandigarh
Date: 11.02.2019

NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab, CIN: L24232PB1995PLC016664

Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: cs@neclife.com, Website : www.neclife.com

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2018

(Rs in Lacs)

S. No	PARTICULARS	Quarter ended			Nine Months ended		Year ended
		31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income from Operations						
	Sales	82,021.24	81,955.49	58,791.82	223,470.55	140,951.22	209,231.93
	Less: GST Recovered	8,897.77	9,706.48	5,662.57	24,827.05	10,346.24	19,240.64
	Revenue from Operations	73,123.47	72,249.01	53,129.25	198,643.50	130,604.98	189,991.29
	Other operating Income	0.63	0.62	30.64	3.77	34.94	45.14
II	Other Income	153.36	144.96	167.51	429.29	431.93	558.44
III	Total Income (I + II)	73,277.46	72,394.59	53,327.40	199,076.56	131,071.85	190,594.87
IV	Expenses						
	(a) Cost of Materials consumed	57,199.38	56,954.71	38,613.55	155,063.45	88,218.73	138,163.89
	(b) Purchase of Stock in Trade	1,627.79	1,198.67	363.54	3,148.64	1,059.76	1,527.31
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(144.11)	390.63	458.30	(503.00)	1,125.65	(3,043.22)
	(d) Excise Duty	-	-	-	-	2,369.13	2,438.15
	(e) Employee benefits expense	2,083.65	2,157.27	2,047.03	6,246.72	5,976.17	7,840.48
	(f) Finance costs	3,599.77	4,355.37	3,069.83	10,947.48	8,503.73	11,520.24
	(g) Depreciation and amortisation expense	1,687.76	1,554.57	1,618.78	4,871.59	4,814.37	6,430.88
	(h) Other expenses	5,789.75	5,161.62	4,867.91	15,729.28	13,362.87	19,460.56
	Total Expenses (IV)	71,843.99	71,772.79	51,038.94	195,504.16	125,430.41	184,338.29
V	Profit/(loss) before exceptional items and tax (III- IV)	1,433.47	621.80	2,288.46	3,572.40	5,641.44	6,256.58
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	1,433.47	621.80	2,288.46	3,572.40	5,641.44	6,256.58
VIII	Tax Expense (1) Current Tax	296.16	26.51	369.24	466.25	729.30	632.18
	(2) Deferred Tax	5.72	55.86	18.97	113.68	85.72	408.92
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	1,131.59	539.43	1,900.25	2,992.47	4,826.42	5,215.48
	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	109.66
	Total Other Comprehensive Income, (Net of Tax)						109.66
	Total Comprehensive Income for the period	1,131.59	539.43	1,900.25	2,992.47	4,826.42	5,325.14
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic	0.50	0.24	0.85	1.33	2.15	2.33
	b) Diluted	0.50	0.24	0.85	1.33	2.15	2.33

Notes:

- 1 The above financial results were reviewed by Audit Committee on February 11, 2019 and approved by the Board in its meeting held on February 11, 2019. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone unaudited financial results for the quarter and nine months ended on December 31, 2018.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 The above financial results are on stand alone basis.

By Order of the Board of Directors
of Nectar Lifesciences Limited

(Dinesh Dua)

Chief Executive Officer & Director

Dated: 11-02-2019

Place: Chandigarh

11/02/2019


 (Anwar J. Gupta)
 M.No. 082808